vildagliptin (Galvus)
Jump to navigation
Jump to search
Introduction
Expected October 2006
Indications
Dosage
Pharmacokinetics
- metabolized by the liver
Adverse effects
- GI: nausea/vomiting, diarrhea, abdominal pain, dyspepsia
- hypoglycemia < 1%
- edema 2.5%
Mechanism of action
- dipeptidyl peptidase-4 inhibitor
- inhibits incretin catabolism
- enhances incretin system
- improves lipid profile
More general terms
References
- ↑ Prescriber's Letter 12(9): 2005 Investigational Medicines for Diabetes: Sitagliptan (Januvia) and Vildagliptan (Galvus) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220715&pb=PRL (subscription needed) http://www.prescribersletter.com